Youssry S, Ghoneim H, Barakat R, ElAlfy E
Sci Rep. 2025; 15(1):5676.
PMID: 39955339
PMC: 11830086.
DOI: 10.1038/s41598-025-88719-5.
Lin R, Lv H, Yu J, Song C, Tian A
Quant Imaging Med Surg. 2024; 14(7):4950-4964.
PMID: 39022246
PMC: 11250318.
DOI: 10.21037/qims-23-1738.
Mallio C, Greco F, Gaudino F, Zobel B, Quattrocchi C
Skeletal Radiol. 2023; 52(8):1567-1575.
PMID: 36961572
DOI: 10.1007/s00256-023-04326-3.
Guo Y, Huang Y, Wang Y, Huang J, Lai Q, Li Y
Comput Math Methods Med. 2022; 2022:2541358.
PMID: 36092784
PMC: 9453096.
DOI: 10.1155/2022/2541358.
Pedersen C, Cao M, Fleischer T, Rye M, Knappskog S, Eikesdal H
Breast Cancer Res. 2022; 24(1):43.
PMID: 35751095
PMC: 9233373.
DOI: 10.1186/s13058-022-01537-9.
The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.
Gahrmann R, Smits M, Vernhout R, Taal W, Kapsas G, de Groot J
Neurooncol Adv. 2022; 4(1):vdac032.
PMID: 35419519
PMC: 9000300.
DOI: 10.1093/noajnl/vdac032.
Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks R, Albanghali M, Syed B, Green A, Ellis I, Cheung K
Breast Cancer Res Treat. 2020; 185(3):647-655.
PMID: 33226492
PMC: 7921046.
DOI: 10.1007/s10549-020-06023-4.
Bone metastases in thyroid cancer.
Iniguez-Ariza N, Bible K, Clarke B
J Bone Oncol. 2020; 21:100282.
PMID: 32154098
PMC: 7058902.
DOI: 10.1016/j.jbo.2020.100282.
Silencing miR-150 Ameliorates Experimental Autoimmune Encephalomyelitis.
Hu Z, Cui Y, Qiao X, He X, Li F, Luo C
Front Neurosci. 2018; 12:465.
PMID: 30050402
PMC: 6052910.
DOI: 10.3389/fnins.2018.00465.
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer.
De Marchi T, Timmermans M, Sieuwerts A, Smid M, Look M, Grebenchtchikov N
Sci Rep. 2017; 7(1):2099.
PMID: 28522855
PMC: 5437008.
DOI: 10.1038/s41598-017-02296-w.
EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Neusquen L, Filassi J, Fristachi C, Carvalho K, Doria M, Soares Junior J
Rev Bras Ginecol Obstet. 2016; 38(6):280-6.
PMID: 27399922
PMC: 10374234.
DOI: 10.1055/s-0036-1584954.
Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study.
Szentmartoni G, Tokes A, Tokes T, Somlai K, Szasz A, Torgyik L
Croat Med J. 2016; 57(2):131-9.
PMID: 27106355
PMC: 4856188.
DOI: 10.3325/cmj.2016.57.131.
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.
Tambe M, Pruikkonen S, Maki-Jouppila J, Chen P, Elgaaen B, Straume A
Oncotarget. 2016; 7(11):12267-85.
PMID: 26943585
PMC: 4914283.
DOI: 10.18632/oncotarget.7860.
Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases.
Quattrocchi C, DellAia P, Errante Y, Occhicone F, Longo D, Virzi V
J Bone Oncol. 2016; 1(1):24-9.
PMID: 26909251
PMC: 4723329.
DOI: 10.1016/j.jbo.2012.02.001.
Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.
De Marchi T, Timmermans A, Smid M, Look M, Stingl C, Opdam M
Oncotarget. 2015; 7(3):3098-110.
PMID: 26657294
PMC: 4823093.
DOI: 10.18632/oncotarget.6521.
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S, Berge E, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B
Mol Oncol. 2015; 9(8):1553-64.
PMID: 26004085
PMC: 5528784.
DOI: 10.1016/j.molonc.2015.04.008.
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.
Wallace T, Torre T, Grob M, Yu J, Avital I, Brucher B
J Cancer. 2014; 5(1):3-24.
PMID: 24396494
PMC: 3881217.
DOI: 10.7150/jca.7709.
Usefulness of traditional serum biomarkers for management of breast cancer patients.
Mirabelli P, Incoronato M
Biomed Res Int. 2013; 2013:685641.
PMID: 24350285
PMC: 3856124.
DOI: 10.1155/2013/685641.
GPER-1 acts as a tumor suppressor in ovarian cancer.
Ignatov T, Modl S, Thulig M, Weissenborn C, Treeck O, Ortmann O
J Ovarian Res. 2013; 6(1):51.
PMID: 23849542
PMC: 3723961.
DOI: 10.1186/1757-2215-6-51.
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.
Ahmed K, Barney B, Davis B, Park S, Kwon E, Olivier K
Front Oncol. 2013; 2:215.
PMID: 23346551
PMC: 3551203.
DOI: 10.3389/fonc.2012.00215.
